Spin-out companies

The APC Microbiome Institute has spun out 3 companies since 2012:

Atlantia 1

Founded in 2012, Atlantia conducts clinical trials for innovative food and supplement companies that want to explore the potential health benefits of functional food ingredients, beverages and supplements. Atlantia developed from expertise within the APC and its experience in conducting clinical trials for the pharmaceutical and food sectors, and works closely with clinicians and scientists in the APC.  Atlantia provides a comprehensive end-to-end solution for human intervention studies, and specialises in trials for functional ingredients in foods, nutraceuticals, medical foods, dietary supplements and infant formula.

If you would like further information, please see the Atlantia website at http://atlantiafoodcro.com/ or contact Barry Skillington, VP for Sales at barry@atlantiafoodcro.com; tel +353(0)86 8181543


  • 4DpharmacorkLOGO4D pharma Cork Ltd (previously Tucana Health Ltd):

4D pharma Cork Ltd is a spin-out from the APC Microbiome Institute founded as Tucana Health in February 2016 by Professors Fergus Shanahan and Paul O’Toole. The focus of the company is to investigate how the composition of bacterial communities in the gut can aid the diagnosis and treatment of disease. Recent advances in the field have highlighted the importance of the gut microbiome, not only for the development of safe and efficacious new therapeutics, but also in the discovery of novel personalised diagnostic tools.

4D pharma Cork Ltd was formerly known as Tucana Health Ltd. before recently being acquired by 4D pharma plc, a pharmaceutical company focusing on the development of live biotherapeutics, a novel and emerging class of drugs. The spin-out company currently with a staff of 6 employees, will help to build further research capability, by providing high end research jobs.  While the initial focus of the spin-out company will be on diagnosis and patient stratification for Irritable Bowel Syndrome (IBS), the long term objective is to build a diagnostic platform across multiple disease areas, mirroring the programmes developed by 4D’s proprietary platform, MicroRx for the discovery of novel live biotherapeutics. For further information please contact Dr Eileen O’ Herlihy Site Manager.

  • Artugen Therapeutics

Artugen Therapeutics is a new spin-out company from the APC Microbiome Institute founded in 2016 by Profs Paul Ross and Colin Hill.  The company is licensing significant IP from the APC Microbiome Institute.   The company will focus on the discovery and development of targeted treatments for bacterial infections.   Artugen Therapeutics has attracted a Series A investment from Morningside Ventures, a top Hong-Kong and US-based international venture company.  Former Cubist Pharma Senior Vice President, Dr. Ronnie Farquhar has been appointed as the CEO.